

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

FHL/SEC/2022-23

May 26, 2022

**The National Stock Exchange of India Ltd.
Corporate Communications Department
“Exchange Plaza”, 5th Floor, Bandra-Kurla
Complex, Bandra (East), Mumbai – 400051
Scrip Symbol: FORTIS**

**BSE Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001
Scrip Code:532843**

**Sub: Intimation of Re-appointment of Independent Directors under Regulation 30 of SEBI
(Listing Obligations & Disclosure Requirements) Regulations, 2015**

Dear Madam / Sir,

Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held on May 25, 2022 have, *inter-alia*, considered and approved the Re-appointment of Mr. Ravi Rajagopal, Ms. Suvalaxmi Chakraborty and Mr. Indrajit Banerjee as Independent Directors of the Company, subject to approval of the shareholders, for the second term of upto 5 years.

Further, the detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/ CFD /CMD/4/2015 dated September 9, 2015 is enclosed as **Annexure A**.

This is for your information and record.

Thanking you,
Yours sincerely,
For **Fortis Healthcare Limited**

**Murlee Manohar Jain
Company Secretary and Compliance Officer
ICSI Membership: F9598**

Encl: a/a

Annexure-A
Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Profile of Mr. Ravi Rajagopal

S. No.	Particulars	Description
1	Reason for change viz. appointment, resignation, removal, death or otherwise.	Re-appointment of Mr. Ravi Rajagopal (DIN: 00067073) as an Independent Director subject to the approval of the shareholders.
2	Date of appointment/cessation (as applicable) & term of appointment.	Re-appointment for the second term of upto 5 years with effect from April 27, 2023.
3	Brief profile (in case of appointment).	<p>Mr. Ravi Rajagopal, aged about 67 years, has been Chairman of Fortis Healthcare since 2018. Mr. Rajagopal led the newly nominated Board in overhauling the governance processes and strengthening the controls.</p> <p>Mr. Rajagopal is Vice Chairman and Independent Director of The Peabody Group, the UK's largest affordable housing company. He is a Director and Audit Chair of Airtel Africa Plc, A FTSE 100 company in the UK. He is a Trustee of the Science Museum Foundation UK, the most iconic Museum of its kind in the world. Earlier board experience includes serving as Director and Audit Chair of globally diversified natural resources company, Vedanta plc (FTSE 250) and a Diageo nominee Director of United Spirits, India from 2013 to 2016.</p> <p>With an extensive career spanning 35 years working in large consumer goods companies, spending the last 20 years with Diageo plc in a variety of senior leadership roles including group controller for the plc and latterly as global head of mergers and acquisitions. Prior to that Mr. Rajagopal was with ITC India across different businesses in India and overseas where he held a number of progressively senior roles. His overall experience includes working in many markets across the world in both a strategic and operational capacity.</p> <p>Mr. Rajagopal is involved with a number of charitable activities. He is Chair of an Advisory Board for a project responsible for building and operating over 8000 childcare centres across northern India; and he is a Trustee of a group of four schools in Chennai that educates over 1,100 underprivileged children at no cost.</p> <p>Mr. Rajagopal is a Chartered and Cost Accountant, he has lived in London since 1998. He has lectured on Behavioural Economics at the Saïd Business School, Oxford University and Imperial College, London.</p>

FORTIS HEALTHCARE LIMITED

4	Disclosure of relationships between directors (in case of appointment of a director).	Not related to any of the Director of the Company
5	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/24 dated June 20, 2018 issued by the BSE and NSE, respectively.	Mr. Rajagopal is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

Profile of Ms. Suvalaxmi Chakraborty

S. No.	Particulars	Description
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Ms. Suvalaxmi Chakraborty (DIN: 00106054) as an Independent Director subject to the approval of the shareholders.
2	Date of appointment/cessation (as applicable) & term of appointment.	Re-appointment for the second term of upto 5 years with effect from April 27, 2023.
3	Brief profile (in case of appointment)	<p>Ms. Suvalaxmi Chakraborty, aged about 55 years, has over 32 years of experience in the field of financial services and banking. She has rich exposure to various facets of banking, including Corporate Banking, Treasury Management, Asset Liability Management, Corporate Risk Management, Micro-Banking and Agri business. She has also featured in the Fortune India List of 50 most powerful women in business.</p> <p>Ms. Chakraborty, currently, is the Founder, CEO & MD of FinReach Solutions Private Ltd., set up by a few international and domestic investors with a view to facilitate credit access for MSMEs. At FinReach, she is responsible to set up the business, technology platform, operationalize the entity and run the day to day operations. Prior to FinReach, she held the position of Co-Founder & Director of Espandere Advisors Pvt. Ltd., providing Business and Transaction Advisory services in Banking & Finance, Agriculture & Rural, Infrastructure and Manufacturing Sector. She has also worked as Advisor, Fullerton India Credit Company Ltd., a 100% step down subsidiary of Temasek Holdings (Pte) Ltd, Singapore.</p> <p>Ms. Chakraborty held several positions at ICICI Ltd. and ICICI Bank between 1989 and 2006, including General Manager for Corporate Banking and Country Head of Rural, Micro-banking and Agri Business.</p>

		<p>She was Director on the Board of Fixed Income Money Markets and Derivatives Association (FIMMDA) for over 2 years and headed the working committee (New Products) in FIMMDA. She has represented ICICI on the Board of Clearing Corporation of India. She launched and ran the commercial banking business of Barclays Bank in India from 2007 to 2010, after which she was Chief-Executive Office for the Indian operations of State Bank of Mauritius from 2010 to 2013. In 2014, she was also Advisor for Transwarranty Finance Ltd. and Positron Consulting Services in its consulting assignments with Private Equity firms, Corporates and NBFCs in the area of Rural, Microbanking and Agri banking.</p> <p>Currently she serves as an Independent Director for SRL Diagnostics and nominee director in Kaleidofin Private Ltd. She has held the position of Independent/ Nominee Director in the past in Magma HDI General Insurance Company Ltd., Caspian Impact Investments Pvt Ltd., IIFL home Finance Ltd. and North East Small Finance Bank Ltd.</p> <p>She is a Chartered Accountant and has a B. Com. (Hons) degree from Calcutta University and in 1999 completed the Financial Investment Technology Program of the Berkeley Program in Finance at HAAS School of Business at University of California, Berkeley, California. In 2002 she participated in the Leading Change and Organizational Renewal Program at the Graduate School of Business, Stanford University, California, and she has also participated in the 'Women on Corporate Boards' initiative initiated by FICCI Centre for Corporate Governance.</p>
4	Disclosure of relationships between directors (in case of appointment of a director).	Not related to any of the Director of the Company
5	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/24 dated June 20, 2018 issued by the BSE and NSE, respectively.	Ms. Chakraborty is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

Profile of Mr. Indrajit Banerjee

S. No.	Particulars	Description
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Indrajit Banerjee (DIN: 01365405) as an Independent Director subject to the approval of the shareholders.
2	Date of appointment/cessation (as applicable) & term of appointment.	Re-appointment for the second term of upto 5 years with effect from April 27, 2023.

FORTIS HEALTHCARE LIMITED

3	Brief profile (in case of appointment)	<p>Mr. Indrajit Banerjee, aged about 66 years, is a Chartered Accountant and has a corporate career spanning over 35 years. Over the last 20 years, he has played a key role in senior leadership positions, principally in Ranbaxy, Cairn India, Lupin and Indal, dealing with unique business criticalities which led to the organisations realising their potential values.</p> <p>Mr. Banerjee has a B. Com. (Hons) degree from St. Xavier's College, Kolkata. In his early career at Brooke Bond India Ltd and Indian Aluminium Co Ltd (Indal), his focus was on establishing sound financial controls in complicated business environment which also facilitated businesses to improve their competitive position. Since then, he has played the role of CFO/Executive Director in companies that experienced difficult business situations of varying nature in complex shareholding situations.</p> <p>Between 1982 and 1999 he was at Indal, of which the final two years he was Chief Financial Officer, where he played a key role in the strategy formation and risk management in the company during the transformation stage. He joined Lupin Ltd. in 2002, where he addressed the critical liquidity challenges faced by the company and led the entry of a set of private equity investors that helped re-brand the company. In 2005, he joined Cairn India Ltd., where he guided the financing of the country's largest greenfield upstream onshore oil and gas development project which was the first large project of its size and complexity in India. He was also President and CFO, and a Member of the Executive Committee, at Ranbaxy Laboratories Ltd between 2011 and 2015, where he helped the company sustain itself through its most challenging times and played a critical role in the process leading to the merger of the company with Sun Pharma, later leading the integration of businesses and processes of the merged entity post-merger.</p> <p>Since November 2015, he has engaged in certain specific management consultancy services, including business structuring and planning; management of growth situations; management of crisis situations through cash flow monitoring, prioritisation of operational requirements and bank relationship management; financing of working capital and establishment of Risk Management processes in multi-business and multi-regional organisations; business and financial process integration for existing organisations as well as for merging entities.</p>
4	Disclosure of relationships between directors (in case of appointment of a director).	Not related to any of the Director of the Company

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

5	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/24 dated June 20, 2018 issued by the BSE and NSE, respectively.	Mr. Banerjee is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.
---	--	---